Adenosine deaminase 2 regulates the activation of the toll-like receptor 9 in response to nucleic acids.

IF 3.9 3区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL
Frontiers of Medicine Pub Date : 2024-10-01 Epub Date: 2024-07-30 DOI:10.1007/s11684-024-1067-5
Liang Dong, Wenwen Luo, Skaldin Maksym, Simon C Robson, Andrey V Zavialov
{"title":"Adenosine deaminase 2 regulates the activation of the toll-like receptor 9 in response to nucleic acids.","authors":"Liang Dong, Wenwen Luo, Skaldin Maksym, Simon C Robson, Andrey V Zavialov","doi":"10.1007/s11684-024-1067-5","DOIUrl":null,"url":null,"abstract":"<p><p>Human cells contain two types of adenosine deaminases (ADA) each with unique properties: ADA1, which is present in all cells where it modulates intracellular functions and extracellular signaling, and ADA2, which is secreted by immune cells. The exact intracellular functions of ADA2 remain undetermined and less defined than those of ADA1. ADA2 has distinct characteristics, such as low adenosine affinity, heparin-binding ability, and putative lysosomal entry. Here, we confirm that ADA2 is a lysosomal protein that binds toll-like receptor 9 (TLR9) agonists, specifically CpG oligodeoxynucleotides (CpG ODNs). We show that interferon-alpha (IFN-α) is secreted in response to TLR9 activation by CpG ODNs and natural DNA and markedly increases when ADA2 expression is downregulated in plasmacytoid dendritic cells (pDCs). Additionally, the pretreatment of pDCs with RNA further stimulates IFN-α secretion by pDCs after activation with CpG ODNs. Our findings indicate that ADA2 regulates TLR9 responses to DNA in activated pDCs. In conclusion, decreasing ADA2 expression or blocking it with specific oligonucleotides can enhance IFN-α secretion from pDCs, improving immune responses against intracellular infections and cancer.</p>","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":" ","pages":"814-830"},"PeriodicalIF":3.9000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers of Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11684-024-1067-5","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/30 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Human cells contain two types of adenosine deaminases (ADA) each with unique properties: ADA1, which is present in all cells where it modulates intracellular functions and extracellular signaling, and ADA2, which is secreted by immune cells. The exact intracellular functions of ADA2 remain undetermined and less defined than those of ADA1. ADA2 has distinct characteristics, such as low adenosine affinity, heparin-binding ability, and putative lysosomal entry. Here, we confirm that ADA2 is a lysosomal protein that binds toll-like receptor 9 (TLR9) agonists, specifically CpG oligodeoxynucleotides (CpG ODNs). We show that interferon-alpha (IFN-α) is secreted in response to TLR9 activation by CpG ODNs and natural DNA and markedly increases when ADA2 expression is downregulated in plasmacytoid dendritic cells (pDCs). Additionally, the pretreatment of pDCs with RNA further stimulates IFN-α secretion by pDCs after activation with CpG ODNs. Our findings indicate that ADA2 regulates TLR9 responses to DNA in activated pDCs. In conclusion, decreasing ADA2 expression or blocking it with specific oligonucleotides can enhance IFN-α secretion from pDCs, improving immune responses against intracellular infections and cancer.

腺苷脱氨酶 2 可调节 toll 样受体 9 对核酸的活化反应。
人体细胞含有两种类型的腺苷脱氨酶(ADA),每种酶都具有独特的特性:ADA1 存在于所有细胞中,可调节细胞内功能和细胞外信号;ADA2 由免疫细胞分泌。ADA2 在细胞内的确切功能仍未确定,不如 ADA1 明确。ADA2 具有独特的特征,如低腺苷亲和力、肝素结合能力以及可能进入溶酶体。在这里,我们证实 ADA2 是一种溶酶体蛋白,能结合收费样受体 9(TLR9)激动剂,特别是 CpG 寡脱氧核苷酸(CpG ODNs)。我们的研究表明,干扰素-α(IFN-α)的分泌是对CpG ODNs和天然DNA激活TLR9的反应,当ADA2在浆细胞树突状细胞(pDCs)中表达下调时,干扰素-α的分泌会明显增加。此外,用 RNA 对 pDCs 进行预处理可进一步刺激 pDCs 在被 CpG ODNs 激活后分泌 IFN-α。我们的研究结果表明,ADA2 可调节活化 pDC 中 TLR9 对 DNA 的反应。总之,减少 ADA2 的表达或用特异性寡核苷酸阻断 ADA2 可增强 pDCs 的 IFN-α 分泌,从而改善对细胞内感染和癌症的免疫反应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Frontiers of Medicine
Frontiers of Medicine ONCOLOGYMEDICINE, RESEARCH & EXPERIMENTAL&-MEDICINE, RESEARCH & EXPERIMENTAL
CiteScore
18.30
自引率
0.00%
发文量
800
期刊介绍: Frontiers of Medicine is an international general medical journal sponsored by the Ministry of Education of China. The journal is jointly published by the Higher Education Press and Springer. Since the first issue of 2010, this journal has been indexed in PubMed/MEDLINE. Frontiers of Medicine is dedicated to publishing original research and review articles on the latest advances in clinical and basic medicine with a focus on epidemiology, traditional Chinese medicine, translational research, healthcare, public health and health policies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信